DIANA OAKES: Open Payments
NPI 1063995249 · ABINGDON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$422 in 23 payments from 8 companies in 2025. Trend: 2023 $27 · 2024 $418 · 2025 $422
Food & beverage: $422
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $117 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $97 |
| Travere Therapeutics, Inc. | 5 | $91 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Novo Nordisk Inc | 1 | $23 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $19 |
| SCPHARMACEUTICALS INC. | 1 | $17 |
Products named: FARXIGA, Kerendia, ACTHAR, Ozempic, TARPEYO, Filspari, BENLYSTA, FUROSCIX.
Industry payments across VA — which companies pay providers there.
